HR 2051 · 115th Congress 2017–2019, ended

FAST Generics Act of 2017

Latest action · Apr 7, 2017 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedApr 6, 2017
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Fair Access for Safe and Timely Generics Act of 2017 or the FAST Generics Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit the license holder of a Food and Drug Administration (FDA)-approved drug or biological product from restricting availability of the medication for testing by a product developer seeking to develop a drug, generic drug, or biosimilar, including restricting availability with a risk evaluation and mitigation strategy (REMS).

Upon request, the license holder of a medication that is not subject to a REMS must provide a product developer with the medication for testing.

For a medication subject to a REMS, a product developer must have FDA authorization to obtain the medication before the license holder must provide it. The FDA may authorize a product developer to conduct testing and clinical trials with the medication.

A wholesaler or specialty distributor who receives a request from a product developer for a medication for testing may not disclose to the license holder the identity of the product developer.

The FDA may prohibit or limit transfer of a medication to a product developer if the transfer poses an imminent hazard to public health.

License holders are not liable for claims arising from a product developer testing a medication.

The FDA may waive the requirement that a medication use a single, shared system of elements to assure safe use with a comparable approved medication if the product developer is unable to finalize terms for a shared system with the license holder of the approved medication.

Cosponsors 13

Members who signed on, in the order they did. Signatures ran from Apr 6, 2017 to Sep 27, 2018; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
D-VTPeter WelchOriginalApr 6, 2017
D-CODiana DeGetteMay 17, 2017
D-ORKurt SchraderMay 17, 2017
R-OHSteve StiversMay 17, 2017
D-ILDaniel LipinskiMay 25, 2017
D-ILJanice D. SchakowskyJun 2, 2017
R-NEJeff FortenberryJun 2, 2017
R-OHJames B. RenacciJul 25, 2017
D-PAMatt CartwrightOct 3, 2017
D-CARo KhannaJul 26, 2018
D-NMMichelle Lujan GrishamSep 7, 2018
R-OHDavid P. JoyceSep 17, 2018
D-CAAmi BeraSep 27, 2018

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Apr 6, 2017
Health Subcommittee
Referred Apr 7, 2017

Actions 3

Everything that happened, newest first.

  1. Apr 7, 2017Referred to the Subcommittee on Health.
  2. Apr 6, 2017Introduced in House
  3. Apr 6, 2017Referred to the House Committee on Energy and Commerce.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: This bill is enacted pursuant to the power granted to Congress under Article I, section 8, Clause 3 of the United States Constitution. The Constitution's Commerce Clause allows Congress to enact laws when reasonably related to the regulation of interstate commerce.

The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 60, April 6, 2017, page H2792.

CRS reports 2

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 2

Products on other subjects that cite it, usually among other measures.

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products, so as to enable eligible product developers to develop and test new products, and for other purposes.
Short Titles as Introduced
FAST Generics Act of 2017
Fair Access for Safe and Timely Generics Act of 2017

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Apr 6, 2017Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.